Hepatitis B Virus
Chronic hepatitis B suppressed viral rebound correlates with T cell responses
Published in Vaccine Weekly, August 30th, 2006
"Despite recent advances in the chemotherapy of CHB, an effective viral suppression after cessation of therapy has not yet been achieved. To investigate whether hepatitis B virus (HBV)-specific T-cell responses are inducible and can contribute to the viral suppression after cessation of the therapy, we conducted a proof-of-concept study with a DNA vaccine comprising of most HBV genes plus genetically engineered interleukin-12 DNA (IL-12N222L) in 12 CHB carriers being treated with lamivudine (LAM)," wrote S.H. Yang and colleagues, Pohang...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-08-30)
More Articles from Vaccine Weekly
- Avian Influenza
Novavax succeeds in making vaccine against new mutation of bird flu - Hepatitis C Vaccine
Priming-boost with adenoviral vector provides efficient hepatitis C immunization - Pediatric Vaccine
Measles, mumps, rubella, and varicella combination vaccine is safe and immunogenic - Schistosomiasis Vaccine
Previous schistosome infections do not compromise efficacy of cercaria vaccine - Vector Development
Live vaccines that deliver antigen by Listeria monocytogenes are compared - Alzheimer Disease
Approaches for immunotherapy for Alzheimer disease are reviewed - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
